Reuters - U.S. drug reviewers might limit the use of a Seattle Genetics Inc experimental blood cancer drug due to the narrow scope of its clinical trials, sending the company's shares down 3.6 percent.
You are here:
Health 
Diseases & Conditions Trial size may limit use of Seattle Genetics drug
(Reuters)
Diseases & Conditions Trial size may limit use of Seattle Genetics drug
(Reuters)
